Results 201 to 210 of about 4,825,321 (354)

Activity of [des-Aspartyl1]-Angiotensin II in Primary Aldosteronism [PDF]

, 1979
Robert M. Carey, Carlos R. Ayers, E. Darracott Vaughan, M J Peach, Steven M. Herf   +4 more
openalex   +1 more source

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen, Aldina Pivodic, Maria Schaufelberger, Annika Rosengren, Michael Fu   +4 more
wiley   +1 more source

ML enhanced bioactivity prediction for angiotensin II receptor: A potential anti-hypertensive drug target. [PDF]

Sci Rep
Sankar J, Rajendran V, Kuriakose BB, Alhazmi AH, Wong LS, Muthusamy K.   +5 more
europepmc   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

GSTP1 inhibits angiotensin II-induced atrial fibrillation by regulating ferroptosis. [PDF]

Europace
Li H, Feng Z, Li B, Bai J, Lin QY, Yu X, Zhang N, Xie Y, Yang X.   +8 more
europepmc   +1 more source

Angiotensin II and its heptapeptide (2-8), hexapeptide (3-8), and pentapeptide (4-8) metabolites in arterial and venous blood of man. [PDF]

, 1976
P F Semple, A S Boyd, Peter Dawes, J J Morton   +3 more
openalex   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

Angiotensin II Mediates Angiotensin Converting Enzyme Type 2 Internalization and Degradation Through an Angiotensin II Type I Receptor–Dependent Mechanism

HYPERTENSION, 2014
Matthew R. Deshotels, Huijing Xia, S. Sriramula, E. Lazartigues, C. Filipeanu   +4 more
semanticscholar   +1 more source

Activity of plasma angiotensin II in experimental coarctation of the aorta

, 1973
Will C. Sealy, P Panijayanond, John C. Alexander, Anthony V. Seaber   +3 more
openalex   +1 more source

N‐terminal pro‐brain natriuretic peptide and cardiorenal outcome in patients with anaemia in chronic kidney disease

ESC Heart Failure, Volume 12, Issue 2, Page 848-858, April 2025.
Abstract Aims Blood levels of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) may be modified by low renal clearance and anaemia. The aim of this study was to investigate the impact of the blood NT‐proBNP level on cardiovascular and renal outcomes in patients with these two manifestations.
Hiroshi Nishi, Masaomi Nangaku, Tadashi Sofue, Tatsuo Kagimura, Ichiei Narita   +4 more
wiley   +1 more source